Abstract: The present invention relates to compounds that can act as inhibitors of ketohexokinase (KHK) and that can be useful in the treatment of diseases and/or disorders associated with KHK. In some embodiments, the present invention relates to compounds and compositions that inhibit KHK and methods for their preparation and use.
Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR such as bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, kidney disorders (including chronic kidney disease), hepatic and colon cancers, and other disorders. The compounds are in the class of sulfinic acid compounds and can be an enantiomer, stereoisomer, tautomer, solvate, hydrate, prodrug, metabolite, or pharmaceutically acceptable salt thereof. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
Type:
Grant
Filed:
August 6, 2019
Date of Patent:
May 24, 2022
Assignee:
Inorbit Therapeutics AB
Inventors:
Rajiv Sharma, Lambertus Benthem, Robert Judkins